Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Qiagen's QIAxpert and Cancer Workbench; Lexogen's RNA-seq Library Prep Kits

Premium

Qiagen has launched QIAxpert for quantification and quality control of DNA and RNA samples for next-generation sequencing. QIAxpert is a UV/VIS spectrophotometer that enables laboratories to effortlessly assess the quality and quantity of nucleic acids in up to 16 samples within just two minutes, according to the company.

Qiagen has also launched the CLC Cancer Research Workbench, a bioinformatics solution for interpretation of next-gen sequencing data for cancer research.


Lexogen has launched QuantSeq 3' mRNA-seq Library Prep, which generates Illumina-compatible libraries of the sequences close to the 3' end of polyadenylated RNA. The kit produces one fragment per transcript in order to give accurate gene expression values.

It has also launched the AutoSense mRNA-seq Library Prep kit, an automated version of its SENSE mRNA-seq kit. It is also compatible with Illumina sequencing as well as automation on PerkinElmer's Sciclone and Zephyr systems.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.